Market Overview

Valeritas Insulin Device For Diabetics Accepted Under Managed Formulary

Valeritas Insulin Device For Diabetics Accepted Under Managed Formulary

Valeritas Holdings (NASDAQ: VLRX) shares are trading higher after the company on Tuesday afternoon announced its V-Go wearable insulin device has been adopted on multiple managed care formularies.

The V-Go is a disposable device for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes, thereby providing an alternative to taking multiple daily insulin injections.

Valeritas shares were trading up 36% at $4 in Wednesday’s pre-market session. The stock has a 52-week high of $34 and a 52-week low of $2.10.

Related Links:

Amneal Announces Restructuring Plan, Cuts Guidance

Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

Posted-In: News Health Care General Best of Benzinga


Related Articles (VLRX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UBS Downgrades Deere, Expects Near-Term Weakness In Farming Equipment Demand

WD-40 Trades Higher On Positive Q3 Earnings